Affordable Access

Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease.

Authors
  • Takahashi, H
  • Tatewaki, W
  • Nagayama, R
  • Hanano, M
  • Tamura, M
  • Yamaguchi, T
  • Takizawa, S
  • Wada, K
  • Shibata, A
Type
Published Article
Journal
Haemostasis
Publication Date
Jan 01, 1987
Volume
17
Issue
6
Pages
353–360
Identifiers
PMID: 3123334
Source
Medline
License
Unknown

Abstract

Cryoprecipitate has proved to correct the hemostatic defects in von Willebrand's disease (vWD) and platelet-type vWD. However, recent studies have revealed that transmission of the AIDS retrovirus (HIV) occurs through exposure to blood products including cryoprecipitate. Treatment with heat-treated factor VIII/von Willebrand factor (vWf) concentrates may have certain advantages over treatment with nonheated products, if these preparations are efficacious in these disorders. We found that a commercially available factor VIII/vWf concentrate, Haemate P, contained the high-molecular-weight multimers of vWf and had a ratio of ristocetin cofactor (RCof) to vWf antigen (vWf:Ag) close to unity. In addition, its capacity to directly induce aggregation of platelet-type vWD platelets in vitro was similar to that for cryoprecipitate. When infused into a patient with platelet-type vWD, Haemate P shortened the prolonged bleeding time and caused spontaneous platelet aggregation in vitro with a mild diminution of platelet count. These results indicate that some of the heat-treated factor VIII/vWf concentrates may provide a safer, yet still effective, treatment for platelet-type vWD.

Report this publication

Statistics

Seen <100 times